Targeting the fatty acid binding proteins disrupts multiple myeloma cell cycle progression and MYC signaling

  1. Mariah Farrell
  2. Heather Fairfield
  3. Michelle Karam
  4. Anastasia D'Amico
  5. Connor S Murphy
  6. Carolyne Falank
  7. Romanos Sklavenitis Pistofidi
  8. Amanda Cao
  9. Catherine R Marinac
  10. Julie A Dragon
  11. Lauren McGuinness
  12. Carlos G Gartner
  13. Reagan Di Iorio
  14. Edward Jachimowicz
  15. Victoria DeMambro
  16. Calvin Vary
  17. Michaela R Reagan  Is a corresponding author
  1. Maine Health Institute for Research, United States
  2. Maine Medical Center Research Institute, United States
  3. Dana-Farber Cancer Institute, United States
  4. University of Vermont, United States
  5. University of New England, United States

Abstract

Multiple myeloma is an incurable plasma cell malignancy with only a 53% 5-year survival rate. There is a critical need to find new multiple myeloma vulnerabilities and therapeutic avenues. Herein, we identified and explored a novel multiple myeloma target: the fatty acid binding protein (FABP) family. In our work, myeloma cells were treated with FABP inhibitors (BMS3094013 and SBFI-26) and examined in vivo and in vitro for cell cycle state, proliferation, apoptosis, mitochondrial membrane potential, cellular metabolism (oxygen consumption rates and fatty acid oxidation), and DNA methylation properties. Myeloma cell responses to BMS309403, SBFI-26, or both, were also assessed with RNA sequencing (RNA-Seq) and proteomic analysis, and confirmed with western blotting and qRT-PCR. Myeloma cell dependency on FABPs was assessed using the Cancer Dependency Map (DepMap). Finally, MM patient datasets (CoMMpass and GEO) were mined for FABP expression correlations with clinical outcomes. We found that myeloma cells treated with FABPi or with FABP5 knockout (generated via CRISPR/Cas9 editing) exhibited diminished proliferation, increased apoptosis, and metabolic changes in vitro. FABPi had mixed results in vivo, in two pre-clinical MM mouse models, suggesting optimization of in vivo delivery, dosing, or type of FABP inhibitors will be needed before clinical applicability. FABPi negatively impacted mitochondrial respiration and reduced expression of MYC and other key signaling pathways in MM cells in vitro. Clinical data demonstrated worse overall and progression-free survival in patients with high FABP5 expression in tumor cells. Overall, this study establishes the FABP family as a potentially new target in multiple myeloma. In MM cells, FABPs have a multitude of actions and cellular roles that result in the support of myeloma progression. Further research into the FABP family in MM is warrented, especially into the effective translation of targeting these in vivo.

Data availability

The clinical datasets used and analyzed during the current study are from Oncomine or data related to accession number GEO:GSE6477. RNA-seq data have been deposited in the NCBI Gene Expression Omnibus (GEO) database with the accession number GSE190699. The mass spectrometry proteomic data have been deposited to the ProteomeXchange Consortium via the PRIDE partner respository with the dataset identifier PXD032829.

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Mariah Farrell

    Center for Molecular Medicine, Maine Health Institute for Research, Scarborough, United States
    Competing interests
    No competing interests declared.
  2. Heather Fairfield

    Center for Molecular Medicine, Maine Health Institute for Research, Scarborough, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8852-2254
  3. Michelle Karam

    Center for Molecular Medicine, Maine Health Institute for Research, Scarborough, United States
    Competing interests
    No competing interests declared.
  4. Anastasia D'Amico

    Center for Molecular Medicine, Maine Medical Center Research Institute, Scarborough, United States
    Competing interests
    No competing interests declared.
  5. Connor S Murphy

    Center for Molecular Medicine, Maine Health Institute for Research, Scarborough, United States
    Competing interests
    No competing interests declared.
  6. Carolyne Falank

    Center for Molecular Medicine, Maine Health Institute for Research, Scarborough, United States
    Competing interests
    No competing interests declared.
  7. Romanos Sklavenitis Pistofidi

    Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    No competing interests declared.
  8. Amanda Cao

    Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    No competing interests declared.
  9. Catherine R Marinac

    Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    Catherine R Marinac, GRAIL Inc: Research Funding; JBF Legal: Consultancy..
  10. Julie A Dragon

    University of Vermont, Burlington, United States
    Competing interests
    No competing interests declared.
  11. Lauren McGuinness

    University of New England, Biddeford, United States
    Competing interests
    No competing interests declared.
  12. Carlos G Gartner

    Center for Molecular Medicine, Maine Health Institute for Research, Scarborough, United States
    Competing interests
    No competing interests declared.
  13. Reagan Di Iorio

    University of New England, Biddeford, United States
    Competing interests
    No competing interests declared.
  14. Edward Jachimowicz

    Center for Molecular Medicine, Maine Health Institute for Research, Scarborough, United States
    Competing interests
    No competing interests declared.
  15. Victoria DeMambro

    Center for Molecular Medicine, Maine Health Institute for Research, Scarborough, United States
    Competing interests
    No competing interests declared.
  16. Calvin Vary

    Center for Molecular Medicine, Maine Health Institute for Research, Scarborough, United States
    Competing interests
    No competing interests declared.
  17. Michaela R Reagan

    Center for Molecular Medicine, Maine Health Institute for Research, Scarborough, United States
    For correspondence
    Michaela.Reagan@MaineHealth.org
    Competing interests
    Michaela R Reagan, Reviewing editor, eLifeOncopeptides Inc, SynDevRx Inc: Research Funding..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2884-6481

Funding

National Cancer Institute (F31CA257695)

  • Connor S Murphy

National Cancer Institute (R37CA245330)

  • Michaela R Reagan

National Cancer Institute (R50CA265331)

  • Heather Fairfield

National Institute of General Medical Sciences (P20GM103449)

  • Julie A Dragon

National Institute of General Medical Sciences (U54GM115516)

  • Michaela R Reagan

National Institute of General Medical Sciences (P20GM121301)

  • Calvin Vary

National Institute of General Medical Sciences (P20GM121301)

  • Michaela R Reagan

American Cancer Society (RSG-19-037-01-LIB)

  • Michaela R Reagan

American Cancer Society (IRG-16-191-33)

  • Michaela R Reagan

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All experimental studies and procedures involving mice were performed in accordance with approved protocols from the Maine Medical Center Research Institute's (Scarborough, Maine, USA) Institutional Animal Care and Use Committee (protocols #2111 or #1812).

Human subjects: Primary human MSCs were isolated from deidentified cancellous bone from the acetabulum received from donors (men and women) after total hip arthroplasty through the MaineHealth Biobank after IRB approval and informed consent (Biobank IRB # 2526).

Copyright

© 2023, Farrell et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,633
    views
  • 344
    downloads
  • 17
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Mariah Farrell
  2. Heather Fairfield
  3. Michelle Karam
  4. Anastasia D'Amico
  5. Connor S Murphy
  6. Carolyne Falank
  7. Romanos Sklavenitis Pistofidi
  8. Amanda Cao
  9. Catherine R Marinac
  10. Julie A Dragon
  11. Lauren McGuinness
  12. Carlos G Gartner
  13. Reagan Di Iorio
  14. Edward Jachimowicz
  15. Victoria DeMambro
  16. Calvin Vary
  17. Michaela R Reagan
(2023)
Targeting the fatty acid binding proteins disrupts multiple myeloma cell cycle progression and MYC signaling
eLife 12:e81184.
https://doi.org/10.7554/eLife.81184

Share this article

https://doi.org/10.7554/eLife.81184

Further reading

    1. Cancer Biology
    2. Immunology and Inflammation
    Sofia V Krasik, Ekaterina A Bryushkova ... Ekaterina O Serebrovskaya
    Research Article

    The current understanding of humoral immune response in cancer patients suggests that tumors may be infiltrated with diffuse B cells of extra-tumoral origin or may develop organized lymphoid structures, where somatic hypermutation and antigen-driven selection occur locally. These processes are believed to be significantly influenced by the tumor microenvironment through secretory factors and biased cell-cell interactions. To explore the manifestation of this influence, we used deep unbiased immunoglobulin profiling and systematically characterized the relationships between B cells in circulation, draining lymph nodes (draining LNs), and tumors in 14 patients with three human cancers. We demonstrated that draining LNs are differentially involved in the interaction with the tumor site, and that significant heterogeneity exists even between different parts of a single lymph node (LN). Next, we confirmed and elaborated upon previous observations regarding intratumoral immunoglobulin heterogeneity. We identified B cell receptor (BCR) clonotypes that were expanded in tumors relative to draining LNs and blood and observed that these tumor-expanded clonotypes were less hypermutated than non-expanded (ubiquitous) clonotypes. Furthermore, we observed a shift in the properties of complementarity-determining region 3 of the BCR heavy chain (CDR-H3) towards less mature and less specific BCR repertoire in tumor-infiltrating B-cells compared to circulating B-cells, which may indicate less stringent control for antibody-producing B cell development in tumor microenvironment (TME). In addition, we found repertoire-level evidence that B-cells may be selected according to their CDR-H3 physicochemical properties before they activate somatic hypermutation (SHM). Altogether, our work outlines a broad picture of the differences in the tumor BCR repertoire relative to non-tumor tissues and points to the unexpected features of the SHM process.

    1. Cancer Biology
    2. Computational and Systems Biology
    Rosalyn W Sayaman, Masaru Miyano ... Mark A LaBarge
    Research Article Updated

    Effects from aging in single cells are heterogenous, whereas at the organ- and tissue-levels aging phenotypes tend to appear as stereotypical changes. The mammary epithelium is a bilayer of two major phenotypically and functionally distinct cell lineages: luminal epithelial and myoepithelial cells. Mammary luminal epithelia exhibit substantial stereotypical changes with age that merit attention because these cells are the putative cells-of-origin for breast cancers. We hypothesize that effects from aging that impinge upon maintenance of lineage fidelity increase susceptibility to cancer initiation. We generated and analyzed transcriptomes from primary luminal epithelial and myoepithelial cells from younger <30 (y)ears old and older >55 y women. In addition to age-dependent directional changes in gene expression, we observed increased transcriptional variance with age that contributed to genome-wide loss of lineage fidelity. Age-dependent variant responses were common to both lineages, whereas directional changes were almost exclusively detected in luminal epithelia and involved altered regulation of chromatin and genome organizers such as SATB1. Epithelial expression variance of gap junction protein GJB6 increased with age, and modulation of GJB6 expression in heterochronous co-cultures revealed that it provided a communication conduit from myoepithelial cells that drove directional change in luminal cells. Age-dependent luminal transcriptomes comprised a prominent signal that could be detected in bulk tissue during aging and transition into cancers. A machine learning classifier based on luminal-specific aging distinguished normal from cancer tissue and was highly predictive of breast cancer subtype. We speculate that luminal epithelia are the ultimate site of integration of the variant responses to aging in their surrounding tissue, and that their emergent phenotype both endows cells with the ability to become cancer-cells-of-origin and represents a biosensor that presages cancer susceptibility.